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SUMMARY 
A long-standing controversy is whether autophagy is a bona fide cause of mammalian 
cell death. We utilized a cell penetrating autophagy-inducing peptide, Tat-Beclin 1, 
derived from the autophagy protein Beclin 1, to investigate whether high levels of 
autophagy result in cell death by autophagy. Here we show that Tat-Beclin 1 induces 
dose-dependent death that is blocked by pharmacological or genetic inhibition of 
autophagy, but not of apoptosis or necroptosis. This death, termed “autosis”, has unique 
morphological features, including increased autophagosomes/autolysosomes and nuclear 
convolution at early stages, and focal swelling of the perinuclear space at late stages. We 
also observed autotic death in cells during stress conditions, including in a subpopulation 
of nutrient-starved cells in vitro and in hippocampal neurons of neonatal rats subjected to 
cerebral hypoxia-ischemia in vivo. A chemical screen of ~5,000 known bioactive 
compounds revealed that cardiac glycosides, antagonists of Na+,K+-ATPase, inhibit 
autotic cell death in vitro and in vivo. Furthermore, genetic knockdown of the Na+,K+-
ATPase α1 subunit blocks peptide and starvation-induced autosis in vitro. Thus, we have 
identified a novel form of autophagy-dependent cell death, an FDA-approved class of 
compounds that inhibit such death, and a crucial role for Na+,K+-ATPase in its regulation. 
These findings have implications for understanding how cells die during certain stress 
conditions and how such cell death might be prevented. 
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INTRODUCTION 
 The lysosomal degradation pathway of autophagy plays a crucial role in enabling 
eukaryotic cells to adapt to environmental stress, especially nutrient deprivation (1). The 
core autophagy machinery was discovered in a genetic screen in yeast for genes essential 
for survival during starvation, and gene knockout or knockdown studies in diverse model 
organisms provide strong evidence for a conserved pro-survival function of autophagy 
during starvation (1). This pro-survival function of autophagy results from its ability to 
mobilize intracellular energy resources to meet the demand for metabolic substrates when 
external nutrient supplies are limited. 
 In contrast to this well-accepted, pro-survival function of autophagy, there has been 
much debate as to whether autophagy – especially at high levels – also functions as a 
mode of cell death (2). Historically, based on morphological criteria, three types of 
programed cell death have been defined, including Type I apoptotic cell death, Type II 
autophagic cell death, and Type III necrotic cell death (3). Autophagic cell death was 
originally defined as a type of cell death that occurs without chromatin condensation and 
is accompanied by large-scale autophagic vacuolization of the cytoplasm. This form of 
cell death, first described in the 1960’s, has been observed ultrastructurally in tissues 
where developmental programs (e.g. insect metamorphosis) or homeostatic processes in 
adulthood (e.g. mammary involution following lactation or prostate involution following 
castration) require massive cell elimination (4-6). Autophagic cell death has also been 
described in diseased tissues and in cultured mammalian cells treated with 
chemotherapeutic agents or other toxic compounds (4-6). 
 The term “autophagic cell death” has been controversial, because it has been applied 
to scenarios where evidence is lacking for a causative role of autophagy in cell death (i.e. 
there is cell death “with autophagy” but not “by autophagy”). However, using more 
stringent criteria to define autophagic cell death (sometimes called “cell death by 
autophagy”), several studies in the past decade have shown that autophagy genes are 
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essential for cell death that occurs in certain tissues in invertebrate development (e.g. 
Drosophila midgut degradation and salivary gland destruction) as well as in cultured 
mammalian cells lacking intact apoptosis pathways – including Bax-/-; Bak-/- murine 
embryonic fibroblasts (MEFs) treated with DNA-damaging agents, mouse fibroblasts 
after caspase 8 inhibition, breast cancer cells with inactive caspase 3 that overexpress 
mutant Beclin 1, and myeloma cells after caspase 10 inhibition (6, 7). In apoptosis-
competent cells, high levels of autophagy can also lead to autophagy gene-dependent, 
caspase-independent cell death, including in cells that express oncogenic H-RasV12 (8) or 
a short isoform of p19ARF (9), or that are exposed to various toxic agents (10). In neonatal 
mice, neuron-specific deletion of Atg7 protects against cerebral hypoxia-ischemia-
induced hippocampal neuron death (11), and in adult rats, shRNA targeting beclin 1 
decreases neuronal death in the thalamus that occurs secondary to cortical infarction (12). 
 While such studies provide genetic support for autophagy as a bona fide mode of cell 
death, the nature of autophagic cell death that occurs in mammalian cells and tissues in 
response to physiological/pathophysiological stimuli remains poorly defined. It is unclear 
whether cells that die “by autophagy” have unique morphological features or a unique 
death machinery. The only morphological feature that has been linked to autophagic cell 
death – autophagic vacuolization – may be observed in cells undergoing apoptotic or 
necrotic cell death, and no proteins aside from the core autophagy proteins have been 
shown to be required for autophagic cell death.  
 Here we identify a novel form of autophagic cell death, autosis, which has unique 
morphological features; depends on the cellular Na+,K+-ATPase; and occurs during 
treatment with autophagy-inducing peptides, starvation, and cerebral hypoxia-ischemia.   
 
 
RESULTS 
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Autophagy-Inducing Peptides Trigger Autophagy-Dependent Cell Death. Previously, 
we discovered a potent autophagy-inducing cell permeable peptide (13), Tat-Beclin 1, 
composed of 11 amino acids of the HIV Tat protein transduction domain, a diglycine 
linker, and 18 amino acids (267-284) derived from the autophagy protein, Beclin 1. This 
peptide induced autophagy without cytotoxicity at low doses, but caused cell death at 
higher doses (13). This finding suggested that the Tat-Beclin 1 peptide might induce a 
form of autophagy-dependent cell death and serve as a model for defining characteristics 
of autophagy-dependent cell death that may occur in pathophysiological settings. 
 We examined the relationship between Tat-Beclin 1-induced autophagy and cell 
death. In HeLa cells, Tat-Beclin 1 led to dose-dependent induction of autophagy, as 
measured by ratios of LC3-II/I and degradation of the autophagy substrate, p62 (Fig. 1A) 
as well as cell death, as measured by a trypan blue exclusion assay (Fig. 1B). Increasing 
durations of exposure to a fixed concentration of Tat-Beclin 1 resulted in a time-
dependent increase in autophagy and cell death (Fig. S1A-B). No autophagy induction or 
cell death was observed after treatment with a control peptide, Tat-Scrambled (13). Thus, 
Tat-Beclin 1 induces cell death in parallel with its ability to induce autophagy in a dose- 
and time-dependent manner. 
   We confirmed that Tat-Beclin 1 induced HeLa cell death by detection of cells 
positive for Sytox Green (a nucleic dye excluded by live cells) (Fig. 1C), an increase of 
propidium iodide (PI)-positive cells (Fig. S1C-D), and a decline of cellular ATP levels 
(Fig. S1E). In addition, Tat-Beclin 1, but not Tat-Scrambled (20 µM, 5 h), significantly 
reduced clonogenic survival (Fig. 1D-E). Tat-Beclin 1 also induced cell death in a variety 
of additional tumor cell lines, in human and rat fibroblasts, and in both primary and 
E1A/Ras-transformed murine embryonic fibroblasts (MEFs) (Fig. S1F). 
 We investigated whether Tat-Beclin 1-induced autophagy is mechanistically related 
to Tat-Beclin 1-induced cell death by using pharmacological and genetic approaches to 
inhibit autophagy. Treatment with 3-methyladenine (3-MA), an inhibitor of Class III 
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phosphatidylinositol 3-kinase (PI3K) activity and autophagosome formation, partially 
blocked Tat-Beclin 1-induced HeLa cell death, as measured by a decreased percentage of 
trypan blue-positive cells (Fig. 1F), increased cellular levels of ATP (Fig. S1G), and 
increased clonogenic survival (Fig. 1G). siRNA knockdown of the essential autophagy 
gene, beclin 1, decreased autophagy in HeLa cells (as measured by p62 degradation) (Fig. 
S1H), and decreased Tat-Beclin 1-induced cell death, as measured by trypan blue 
exclusion (Fig. 1H) and clonogenic survival (Fig. 1I). Furthermore, doxycycline-
inducible shRNA knockdown of ATG13 or ATG14 in U2OS cells decreased Tat-Beclin 1-
induced autophagy (Fig. S1I) and protected against Tat-Beclin 1-induced cell death, as 
measured by trypan blue exclusion (Fig. 1J) and clonogenic survival (Fig. 1K). Blockade 
of autophagosomal/lysosomal fusion by bafilomycin A1, a vacuolar proton ATPase 
inhibitor, did not reduce Tat-Beclin 1-induced cell death (Fig. S1J), suggesting that this 
form of cell death does not require late stages of autophagy. In addition, another 
autophagy-inducing peptide, Tat-vFLIP α2 (which acts by releasing ATG3 from cellular 
FLIP) (14), also induced autophagy (Fig. S1K) that was associated with dose- and time-
dependent cell death (Fig. S1L, S1M) which was reduced by ATG14 knockdown in U2OS 
cells (Fig. S1N). Thus, autophagy-inducing peptides trigger cell death that requires the 
autophagy machinery. 
 
Autophagy Peptide-Induced Death Does Not Require Apoptotic or Necropoptotic 
Machinery. We next asked whether the apoptosis and/or necroptosis death machinery is 
involved in Tat-Beclin 1-induced cell death. We found that neither z-VAD, an inhibitor 
of caspases and apoptosis, nor necrostatin-1 (Nec-1), an inhibitor of RIPK1 kinase-
mediated necroptosis, rescued Tat-Beclin 1-induced cell death as measured by trypan 
blue exclusion (Fig. 1F), levels of cellular ATP (Fig. S1G) or clonogenic survival (Fig. 
S2A). Adenovirus E1A/Ras-transformed MEFs with null mutations in the two pro-
apoptotic genes, Bax and Bak, were susceptible to Tat-Beclin 1-induced cell death (Fig. 
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2A-B) but were resistant to death induced by the apoptosis-inducing agents, staurosporine 
and etoposide (Fig. S2B). Genetic deletion of two key regulators of necroptosis, Ripk1 
and Ripk3, failed to protect primary MEFs from Tat-Beclin 1-induced cell death (Fig. 2C-
D). Thus, neither the apoptotic nor necroptotic death machinery is required for Tat-Beclin 
1-induced cell death. 
 Additional assays confirmed the lack of apoptosis in Tat-Beclin 1-induced death. In 
contrast to staurosporine, Tat-Beclin 1 treatment did not activate caspase 3, as shown 
biochemically by the lack of cleavage of caspase 3 or its substrate PARP (Fig. 2E) and by 
the lack of immunofluorescence staining for active caspase 3 (Fig. 2F). In addition, 
minimal pan-caspase activity was detected in Tat-Beclin 1-treated cells, as measured by 
flow cytometry using a carboxyfluorescein-conjugated general caspase inhibitor, VAD-
FMK (Fig. S2C-D). Consistent with non-apoptotic cell death, no TUNEL (terminal 
deoxynucleotidyl-transferase dUTP nick end labeling) staining (Fig. S2E) or DNA ladder 
formation (Fig. S2F) was detected in Tat-Beclin 1-treated cells. We also confirmed that 
Tat-Beclin 1 (derived from a structurally flexible region in the Beclin 1 evolutionarily 
conserved domain (15)) did not exhibit a pore-forming ability to release cytochrome c 
from mitochondria (Fig. S2G), as do certain other amphipathic α-helical peptides (16). 
Furthermore, various antioxidants that block ROS-mediated cell death failed to rescue 
Tat-Beclin 1-induced cell death (Fig. S2H). Similar to Tat-Beclin 1, Tat-vFLIP α2 also 
failed to induce caspase 3 or PARP cleavage (Fig. S2I). Thus, taken together, our data 
indicate that autophagy-inducing peptide triggered cell death is genetically and 
biochemically distinct from apoptosis or necroptosis. 
 
Autophagy Peptide-Induced Cell Death Has Unique Morphological Features. To 
characterize the nature of this autophagy-dependent, non-apoptotic and non-necrotic cell 
death, we performed live-cell imaging of Tat-Beclin 1-treated cells (Fig. 3A, Video S1, 
S2). During the initial phase after treatment, cells exhibit relatively normal morphology 
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with increased vacuolar dynamics and the perinuclear accumulation of numerous 
vacuoles. After a few hours, cells undergo an abrupt demise (lasting ~15-20 min) 
characterized by the rapid shrinkage of the nucleus with a portion of its surface 
developing a concave appearance corresponding to a round, vacuole-like entity, reflecting 
(based on our EM data; see below) a local separation of the inner and outer nuclear 
membranes. This is followed by focal plasma membrane rupture and extracellular 
extrusion of cytoplasmic contents. Cells treated with Tat-Beclin 1 display increased 
substrate adherence that persists until their final demise (unlike apoptotic or necrotic cells, 
which generally float). 
 The concave nuclear appearance observed in Tat-Beclin 1-induced cell death is 
associated with abnormalities in nuclear lamin A/C staining (lack of a uniform circular 
appearance and presence of focal regions of dense staining) (Fig. 3A, Fig. S3A). Tat-
Beclin 1-treated dying cells also exhibit an abnormal fragmented pattern of Tom20 
(mitochondrial marker) and PDI (endoplasmic reticulum [ER] marker) staining, and a 
striking increase in expression of LAMP1, a marker of late endosomes/autolyosomes 
(which would be expected in the setting of a robust autophagy response) (Fig. 3B). Tat-
vFLIP α2-treated dying cells have a similar concave nuclear appearance and similar 
abnormalities in lamin A/C, Tom 20, PDI, and LAMP1 staining (Fig. S3B). 
 We performed ultrastructural analyses to further characterize the morphology of Tat-
Beclin 1-induced death (Fig. 3C, Fig. S3C). As apparent from live-cell imaging, there 
were two phases of the death process; phase 1 is characterized by a slow phase of gradual 
change and phase 2 is characterized by an abrupt phase of final collapse and cell death. 
Morphologically, phase 1 can be divided into two phases. In phase 1a, the nucleus 
becomes convoluted (but the perinuclear space is normal); chromatin is moderately 
condensed, forming darker regions in the nucleus with borders that are fuzzy (in contrast 
to clumps of chromatin that typically have sharp borders in apoptosis); many of the 
mitochondria are electron-dense and some have an abnormal internal structure (clumps 
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instead of bands); the ER is dilated and fragmented; and numerous autophagosomes, 
autolysosomes, and empty vacuoles are present. In phase 1b, the perinuclear space 
becomes swollen at discrete regions surrounding the inner nuclear membrane, and these 
swollen areas contain membrane-bound regions with a density and granularity resembling 
the cytosol. In some cases, the perinuclear space extends through substantial distances in 
the cytoplasm. In phase 2, there is focal ballooning of the perinuclear space (which 
appears empty), often associated with a concavity of the nuclear surface. At this late stage, 
the morphology appears necrotic; mitochondria and other organelles are swollen; and 
autophagosomes, autolysosomes, and ER are rare. There appears to be lysis of the plasma 
membrane (which is difficult to discern from EM analyses but is substantiated by the 
propidium iodide staining, Sytox Green staining, and live-cell imaging of Tat-Beclin 1-
treated cells).  
 These ultrastructural changes are distinct from previously classifications of cell death 
(3), including type 3B “cytoplasmic death” (also called paraptosis) which also has 
perinuclear swelling. In type 3B cell death, the perinuclear swelling is moderate and 
uniform around the entire nuclear perimeter, whereas in death of autophagy-inducing 
peptide-treated cells, there is a pronounced ballooning in a focal region of the perinuclear 
space. To avoid confusion with terms such as “autophagic cell death” (which is 
sometimes applied to states in which it is not clear that autophagy is required for cell 
death and/or in which autophagic features co-exist with apoptosis or necrosis), we coined 
the term “autosis” to define cell death mediated by autophagy genes and characterized by 
focal perinuclear swelling. We note that several other studies have described “cell death 
by autophagy” i.e. cell death that is blocked by genetic inhibition of autophagy (6). 
However, to our knowledge, such studies have not described increased substrate 
adherence and focal perinuclear swelling of dying cells; thus, autosis represents a newly 
described form of cell death by autophagy.  
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Starvation Induces Autosis. We next investigated whether autosis occurs during 
physiological stress conditions associated with high levels of autophagy. Nutrient 
starvation is the most potent known physiological inducer of autophagy in eukaryotic 
cells, and previous studies have shown that autophagy delays apoptosis in cells subjected 
to starvation, including HeLa cells (1). However, upon subjecting HeLa cells to amino 
acid and serum starvation, we found that, unlike the vast majority of cells which detach 
from their substrate and undergo apoptosis (as evidenced by active caspase 3 staining), a 
small subpopulation (~1%) of cells become more substrate-adherent and lack evidence of 
caspase 3 activation (Fig. 4A). This population of substrate-adherent, caspase 3-negative 
cells undergoes plasma membrane rupture and cell death, as identified by Sytox Green 
staining (Fig. 4B), and also displays a marked increase (~3-fold) in number of 
autophagosomes (GFP-LC3 puncta) as compared to the number of autophagosomes in 
the majority population of starved cells that float and undergo apoptosis (Fig. 4C-D). 
These substrate-adherent cells have nuclei with concave regions and focal swelling of the 
perinuclear space (Fig. 4A-C, E) and display similar abnormalities in lamin A/C staining 
as observed in Tat-Beclin 1 and Tat-vFLIP α2 peptide-treated cells (Fig. 4B, Fig. S3B). 
Similar to Tat-Beclin 1 peptide treatment, we observed phase 1 starved cells with 
increased autophagosomes/autolysosomes, and regions of perinuclear swelling containing 
organelles as well as phase 2 cells with rare autophagosomes/autolysosomes and dilated 
regions in the perinuclear space (Fig. 4E). We also observed similar features of autosis in 
starved adherent bone marrow-derived murine macrophages (BMDMs) and primary 
MEFs (Fig. 4F), suggesting that starvation-induced autosis occurs in primary cells and is 
not merely a consequence of mutations that confer resistance to apoptosis in continuous 
cell lines. Moreover, the frequency of autotic cell death was higher (~5%) in primary 
cells compared to in HeLa cells. 
 To confirm that autophagy is required for starvation-induced death in cells with 
autotic morphology, we assessed the effects of autophagy gene knockdown on the 
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clonogenic survival of substrate-adherent starved cells. In this assay, floating (apoptotic 
and necrotic) cells were washed away after 48 h (HeLa cells) or 72 h (U2OS cells and 
BMDMs) starvation, and the clonogenic potential of the remaining adherent cells was 
assessed (Fig. S4A). Both ATG7 and beclin 1 siRNA treatment (Fig. S4B) increased 
numbers of colonies formed by starved adherent HeLa cells (Fig. 4G), and ATG14 
shRNA expression (Fig. S4C) increased numbers of colonies formed by starved adherent 
U2OS cells (Fig. 4H). Lysozyme:Cre-mediated deletion of Atg5 (Fig. S4D) also 
increased numbers of colonies formed by starved adherent Atg5flox/flox BMDMs (Fig. 4I). 
(ATG7 siRNA, beclin 1 siRNA, ATG14 shRNA and Atg5 deletion had minimal effect on 
the clonogenic survival of cells cultured in normal media (Fig. S4B-C, E)). Thus, 
autophagy genes are required for starvation-induced autosis.  
 
Autosis Occurs during Rat Cerebral Hypoxic-Ischemic Injury. After establishing 
ultrastructural criteria for autosis in cultured cells, we evaluated whether autosis occurs in 
vivo. We performed electron microscopic analysis of neuronal death following cerebral 
hypoxia-ischemia in the brains of neonatal rats (Fig. 5); we focused on dying neurons in 
the hippocampus CA3 region because we had previously shown that most of these 
neurons degenerate with autophagic features (from 6 h after hypoxia-ischemia) without 
signs of apoptosis or necrosis (17). At 24 h after cerebral hypoxia-ischemia, most of the 
dying neurons displayed strong autophagic features such as numerous autophagosomes 
and autolysosomes, and empty vacuoles (phase 1a). Strikingly, some neurons also 
showed focal ballooning of the perinuclear space characteristic of phase 1b of autosis. 
Other dying neurons displayed the archetypal phase 2 feature of autosis, focal ballooning 
of the perinuclear space associated with nuclear concavity. Thus, autotic cell death occurs 
in certain pathophysiological settings in vivo. 
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A High-Throughput Chemical Screen Identifies Cardiac Glycosides as Potent 
Inhibitors of Autosis. To gain insight into the regulation of autosis, we performed high-
throughput compound screening to identify inhibitors of Tat-Beclin 1-induced cell death, 
focusing on compound libraries consisting of bioactive agents with known targets. We 
measured levels of cellular ATP (as a proxy of cellular viability) 5 h after Tat-Beclin 1 
treatment of HeLa cells in the presence of ~5,000 FDA-approved drugs and bioactive 
compounds with characterized mechanisms of action (Fig. S5A). We chose for further 
analysis the 36 top hits that had z-scores > 3.0 in the primary screen (Fig. 6A, Table S1). 
These 36 hits were classified into 9 families based on their chemical structures and/or 
biological functions (Table S2). Of these 36 hits, 8 compounds demonstrated > 40% 
rescue of autosis in a repeat ATP assay and were chosen for further analysis (Table S3). 
Of these 8 compounds, only 5, including three cardiac glycosides (digoxin, digitoxigenin, 
and strophanthidin) and two purinergic receptor antagonists (suramin and NF 023) 
demonstrated more than 80% rescue of Tat-Beclin 1 peptide-induced cell death as 
measured by Sytox Green staining (Fig. S5B). The purinergic receptor antagonists, but 
not the cardiac glycosides blocked cellular peptide entry, as quantified by the cells that 
stained positive for a biotin-conjugated version of Tat-Beclin 1 in the presence of 
compound (Fig. S5C-D), and therefore, were not studied further. Thus, our chemical 
screen identified cardiac glycosides as the only class of agents that inhibited the Tat-
Beclin 1-induced cell death without blocking cellular peptide entry. 
 To assess the significance of the effects of cardiac glycosides on autosis in an 
unbiased manner, we tested whether the nine cardiac glycosides present in our library 
were statistically enriched among top-scoring compounds. We calculated a weighted 
Kolmogorov-Smirnov-like statistic, the normalized enrichment score (NES), using 
Compound Set Enrichment Analysis (CSEA). CSEA demonstrated strong, highly 
significant enrichment for cardiac glycosides (P<10-4) (Fig. 6B). In addition to the three 
cardiac glycosides with z-scores >3.0 in the primary screen, we confirmed that other 
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cardiac glycosides in the compound libraries also exhibited a significant rescue effect 
(Table S4), as did a cardiac glycoside, neriifolin, which was not in the compound 
libraries and is known to exert neuroprotective actions (18) (Fig. S5E). We also 
performed CSEA using other previously identified compound sets for autophagy inducers, 
specific necrosis inducers, and specific apoptosis inducers (19); none of these sets were 
enriched among our top-scoring compounds (Fig. 6B). While there are previous reports 
that cardiac glycosides may induce basal autophagy (20, 21), an extensive set of 
autophagy inducers drawn from the literature were overrepresented among compounds 
that enhanced, rather than rescued, Tat-Beclin 1-induced cell death. The lack of 
concordance between compounds that inhibited autophagy, apoptosis, or necrosis with 
the rescue of Tat-Beclin 1-induced autosis is consistent with the latter representing a 
distinct death process. 
 Consistent with these bioinformatics analyses, the cardiac glycoside, digoxin, had no 
effect on apoptotic death induced by staurosporine or necrotic death induced by H2O2 
(Fig. S5F-G) whereas digoxin, as well as digitoxigenin and strophanthidin, rescued Tat-
Beclin 1–induced cell death with IC50 values below 0.1 µM (Fig. S5H). Digoxin also 
rescued Tat-vFLIP α2-induced death in HeLa cells (Fig. S5H) and Tat-Beclin 1-induced 
cell death in U2OS cells (Fig. S5I). We also found that clonogenic survival was rescued 
in Tat-Beclin 1-treated HeLa cells by digoxin, digitoxigenin and strophanthidin (Fig. 6C); 
in Tat-vFLIP α2-treated HeLa cells by digoxin (Fig. 6D); and in the adherent 
subpopulation of HeLa cells subjected to prolonged starvation by digoxin (Fig. 6E) and 
neriifolin (Fig. 6F). Thus, cardiac glycosides rescue cell death triggered by multiple 
inducers of autosis. 
 Digoxin reversed the majority of morphological abnormalities in cells undergoing 
Tat-Beclin 1-induced autosis. By light microscopy, in the presence of digoxin, Tat-Beclin 
1-treated cells displayed minimal nuclear abnormalities and lacked abnormal patterns of 
mitochondrial (Tom 20), ER (PDI), late endososome/lysosome (LAMP1), and nuclear 
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lamin A/C staining (Fig. 6G). At the ultrastructural level, the majority of digoxin-rescued 
cells demonstrated a normal shaped nuclear membrane without any focal swelling of the 
perinuclear space; intact ER structure; and the absence of increased numbers of 
autophagosomes and autolysosomes (Fig. 6H). The only morphological abnormality of 
autosis not reversed by digoxin in Tat-Beclin 1 treated cells was the presence of electron-
dense mitochondria; however, digoxin alone (in the absence of Tat-Beclin 1) resulted in 
the appearance of electron-dense mitochondria (Fig. S5J). Together, these data indicate 
that digoxin reverses the morphological changes of autosis except for mitochondrial 
abnormalities, but these do not appear to be related to cell death. 
 We performed western blot analyses of LC3 and p62 and quantitation of GFP-LC3 
puncta to further evaluate the effects of digoxin on autophagy. Under basal conditions, 
consistent with prior reports (20, 21), we observed a dose-dependent increase in LC3-II 
conversion and mild reduction in p62 levels (although we did not detect an increase in 
GFP-LC3 puncta) (Fig. 6I, Fig. S5K). In contrast, doses as low as 100 nM resulted in a 
mild decrease in starvation-induced autophagy and a more dramatic decrease in Tat-
Beclin 1-induced autophagy, as measured by increased p62 protein levels, a mild 
decrease in the ratio of LC3-II/LC3-I, and a marked decrease in numbers of GFP-LC3 
puncta (Fig. 6I, Fig. S5K). The increased p62 accumulation was not due to changes in 
p62 mRNA expression (Fig. S5L). Although cardiac glycosides have been reported to 
induce apoptosis (22, 23), we did not observe caspase activation in Tat-Beclin 1-treated 
cells in the presence of digoxin (Fig. S5M).  
 
The Na+,K+-ATPase Regulates Autosis. Cardiac glycosides are inhibitors of Na+,K+-
ATPase, a plasma membrane pump that generates Na+ and K+ gradients across the 
membrane and acts as a versatile signal transducer (22). We therefore examined whether 
Na+,K+-ATPase regulates autosis using siRNA knockdown of the α1 subunit of Na+,K+-
ATPase. Similar to digoxin treatment, Na,K-α1-subunit knockdown (Fig. S6A-B) resulted 
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in a mild decrease in starvation-induced autophagy and a more dramatic decrease in Tat-
Beclin 1-induced autophagy (as measured by increased levels of p62 and decreased GFP-
LC3 puncta) (Fig. 7A, Fig. S6A). The observed increase in p62 accumulation was not due 
to changes in p62 mRNA expression (Fig. S6C) or to a block in peptide delivery into 
cells (Fig. S6D). In parallel with inhibition of autophagy, three different siRNAs against 
Na,K-α1 inhibited Tat-Beclin 1- and Tat-vFLIP α2-induced death, as measured by a 
Sytox Green assay (Fig. 7B). They also increased clonogenic survival of Tat-Beclin 1-
treated cells (Fig. 7C) and adherent cells subjected to starvation (Fig. 7D). Na,K-α1 
siRNA also exerted a protective effect against autosis in human U2OS (Fig. S6E-F) and 
in mouse NIH3T3 (Fig. S6G-H) cells. Digoxin did not enhance Na,K-α1 siRNA-
mediated protection against autosis triggered by autophagy-inducing peptides (Fig. S6I), 
suggesting that digoxin and Na+,K+-ATPase inhibition block autosis through the same 
mechanism.  
 
Cardiac Glycoside-Mediated Protection Against Neuronal Autosis in Rat Cerebral 
Hypoxia-Ischemia. A previous chemical screen to identify compounds that provide 
neuroprotection in a mouse brain slice-based model for ischemic stroke revealed 
neriifolin as a strong hit, and whole animal studies have shown that neriifolin and other 
cardiac glycosides provide significant neuroprotection in neonatal models of cerebral 
hypoxia-ischemia (18, 24, 25). Given these observations, coupled with our findings 
described above that rat hippocampal CA3 region neurons die by autosis following 
hypoxia-ischemia, we evaluated whether neriifolin could protect neonatal rats against 
cerebral hypoxia-ischemia and reduce autosis in the hippocampal region CA3.   
  In agreement with a previous study in mice (18), we found that neriifolin was highly 
neuroprotective in rats; it dramatically increased the volume of intact tissue in the 
ipsilateral hemisphere of neonatal animals one week after cerebral hypoxia-ischemia (Fig. 
8A-B). This effect was particularly notable in the hippocampus (Fig. 8B, Fig. S7A), where 
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significant neuronal pathology, especially in the CA3 region, was detected as early as 24 
h after hypoxia-ischemia injury (Fig. S7B). The CA3 region of the hippocampus, as 
analyzed by examination of Nissl-stained sections, was protected at 24 h and 7 days after 
neonatal hypoxia-ischemia by neriifolin treatment as compared to vehicle-treated pups 
(Fig. S7A-B). In parallel with this neuroprotection, neriifolin prevented the increase in 
autophagy in the CA3 region of the hippocampus that occurred after hypoxia-ischemia 
injury, as measured by detection of decreased numbers of endogenous LC3 puncta and 
LAMP1 puncta by immunofluorescence and immunoperoxidase staining (Fig. 8C, S7C) 
and decreased levels of LC3-II (Fig. 8D-E). Strikingly, in contrast to the characteristic 
features of autosis (numerous autophagosomes, autolysosomes, and empty vacuoles; 
abnormal mitochondria and ER; focal separation of the inner and outer nuclear membrane) 
observed in the CA3 region of vehicle-treated pups 24 h after cerebral hypoxia-ischemia, 
the CA3 region neurons of neriifolin-treated animals displayed no ultrastructural features 
associated with autosis (Fig. 8F). Thus, cardiac glycosides block the increase in 
autophagy and protect hippocampal neurons against cerebral hypoxia-ischemia-induced 
autosis in vivo.  
 
DISCUSSION 
Our findings identify a novel form of autophagic cell death – autosis – that meets two 
essential criteria put forth by the cell death nomenclature committee (2); specifically (1) 
such death must be suppressed by inhibition of the autophagic pathway; and (2) such 
death must be distinct from apoptosis and necrosis. Although several studies have 
described cell death that meets these criteria, the role of autophagy as a mediator of cell 
death has remained controversial. The form of death that we observed in adherent cells 
subjected to starvation and in cells treated with autophagy-inducing peptides not only 
meets both these criteria for “autophagic cell death” but also has a distinctive 
morphological and chemical inhibition signature. In addition to the classical 
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morphological criteria of autophagic cell death (increased autolysosomes in dying cells 
lacking features of apoptosis and necrosis), death induced in starved adherent cells and by 
autophagy-inducing peptides is accompanied by ER dilation and stereotypic nuclear 
changes, involving an early convoluted appearance, the formation of focal concave 
regions of the nucleus with surrounding focal swelling of the perinuclear space, and the 
accumulation of structures within this space at early stages of the process. This form of 
cell death, but not apoptosis or necrosis, is also selectively blocked by pharmacological 
and genetic inhibition of Na+,K+-ATPase. 
 Although the underlying mechanisms of the morphological changes of autosis and the 
pathway by which Na+,K+-ATPase mediates autosis remain to be determined, the 
discovery of this unique morphological and chemical inhibition signature has important 
biological implications. Our findings pave the road to the discovery of physiological and 
pathophysiological conditions in which autophagy functions as a death mechanism, and 
may provide a candidate treatment for diseases in which such death contributes to 
pathogenesis. For example, using the morphological criteria we established for autosis in 
cells subjected to starvation or treatment with autophagy-inducing peptides, we identified 
the presence of autotic death in rat hippocampal neurons subjected to hypoxic-ischemic 
injury. Moreover, we showed that a class of FDA-approved chemical compounds – 
cardiac glycosides – that inhibited autosis in an in vitro chemical compound screen also 
reduced hippocampal neuronal autosis and conferred neuroprotection in vivo in neonatal 
rats subjected to cerebral hypoxia-ischemia. Thus, by defining a novel form of autophagic 
cell death and by performing an in vitro chemical screen that identified a specific class of 
inhibitors of this form of cell death (e.g. cardiac glycosides), we have been able to 
establish a scientific rationale for the use of cardiac glycosides in the treatment of a 
clinically important disease, neonatal cerebral hypoxia-ischemia. Based on our 
identification of specific morphological criteria for autosis, it should be possible to 
determine additional pathophysiological settings in which autosis plays a role and which 
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may be ameliorated by cardiac glycosides. Conversely, mediators in the regulatory 
network of autosis may serve as candidate targets in cancer chemotherapy or other 
settings where pharmacological induction of cell death may be beneficial. 
 We found that autosis occurs in at least two distinct physiological/pathophysiological 
conditions, starvation and cerebral hypoxia-ischemia. At present, it is not yet known 
which, if any, previously reported instances of autophagic cell death involve autosis 
(except for hypoxia-ischemia-induced hippocampal region CA3 death evaluated in this 
study). It is possible that the unique morphological changes we describe for autosis are 
present but have been missed in observations of autophagic cell death in other settings, 
especially those that lack concurrent features of apoptosis or necrosis and/or in tissues 
(e.g. heart and kidneys) where high levels of autophagy are postulated to play a role in 
ischemia-reperfusion injury (26, 27). While the future identification of specific 
biochemical markers of autosis will facilitate such investigations, it should be possible to 
determine whether cell death occurs via autosis using the morphological criteria we 
describe as well as studies examining the inhibitory effect of cardiac glycosides.  
 Although we are not aware of previous reports of similar nuclear morphological 
abnormalities in autophagic cell death, the expression of sterol reductases that are 
localized to the ER and outer nuclear membrane, TM7SF2 and DHCR1, results in 
massive ER and perinuclear space expansion resembling that observed in autotic cells 
(28). These observations suggest that disruption of ER/outer nuclear membrane 
cholesterol metabolism may produce the phenotype of ER and focal perinuclear space 
expansion. This phenotype is possibly caused by alterations of ER membrane properties 
including transport or channel conductance, which would result in osmotic changes and 
disruption of signaling through the nuclear envelope. Given the crucial role of the ER in 
autophagosomal biogenesis (29), we speculate that stimulation of very high levels of 
autophagy may perturb normal ER membrane biogenesis/homeostatic mechanisms, 
leading to similar expansions of the ER lumen and perinuclear space. Further studies are 
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needed to investigate the underlying mechanisms of the morphological abnormalities 
observed in autosis.  
 Cardiac glycosides, a large family of naturally-derived steroidal compounds, were 
first described for the treatment of heart diseases in 1785 (22). Approximately 50 years 
ago, Na+,K+-ATPase was identified as the cellular target of cardiac glycosides. This 
membrane protein uses energy from hydrolysis of ATP to facilitate the transport of 
potassium ions into cells and sodium ions out of cells; inhibition of Na+,K+-ATPase 
results in an increase in intracellular sodium and calcium ions. Cardiac glycosides also 
have diverse effects on cellular signaling, proliferation, metabolism, survival, gene 
expression, attachment, and protein trafficking. To our knowledge, cardiac glycosides 
have not previously been shown to inhibit autophagy or autophagic cell death, and in 
contrast, induce apoptosis in cancer cells (22). Our chemical screen revealed cardiac 
glycosides as the most potent inhibitors of autotic cell death, and we found that they 
inhibited both autophagy and autotic cell death in the setting of starvation, autophagy-
inducing peptide treatment, and neonatal hippocampal hypoxic-ischemic injury.  
 The mechanism of action appears to be inhibition of the known target of cardiac 
glycosides, Na+,K+-ATPase, as we observed similar effects with Na+,K+-ATPase α1 
subunit siRNA knockdown in human and mouse cells. We speculate that the known 
effects of the Na+,K+-ATPase on increasing cell attachment (30) may contribute to the 
increased substrate adherence of cells undergoing autotic death. In addition, it is possible 
that nuclear envelope-associated Na+,K+-ATPase activity (31) may alter membrane ionic 
transport and osmolarity and thereby, contribute to the ER and perinuclear space 
expansion observed in autotic cells. 
 Previous studies have shown that neriifolin and other cardiac glycosides reduce 
cerebral infarct size in rodent cerebral hypoxia-ischemia models (18, 24, 25); however, 
their mechanism of neuroprotection has been unknown. Our observations suggest that 
inhibition of autophagy and autophagy-dependent death pathways may be a central 
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mechanism of cardiac glycoside-mediated neuroprotection. Several cell death 
morphologies have been identified in different regions of the brain after neonatal 
hypoxic-ischemic injury, but neuron-specific deletion of Atg7 or intracerebroventricular 
treatment with the autophagy inhibitor, 3-MA, is sufficient to reduce infarct lesion 
volume, indicating that autophagy may be upstream of multiple death pathways. This 
supports our previous recommendation that postischemic treatment of neonatal cerebral 
hypoxia-ischemia should target autophagy (17, 32)`. In the present study, we observed 
inhibition of autophagy and autotic cell death in hippocampal CA3 region neurons of rats 
treated with neriifolin, but the inhibition of autotic cell death in this region of the 
hippocampus is not sufficient to explain the dramatic reduction in overall ipsilateral 
infarct size following hypoxia-ischemia. Taken together with previous studies on 
autophagy, cell death and neonatal cerebral hypoxia-ischemia, the most likely 
explanation for the overall neuroprotection in neriifolin-treated rats is the blockade of 
both autophagy-dependent autotic death as well as other death pathways triggered by 
high levels of autophagy. Thus, cardiac glycosides and/or other agents targeting Na+,K+-
ATPase may not only ameliorate diseases associated with autotic cell death, but also 
diseases in which autophagy is upstream of other death execution pathways. We cannot 
definitely rule out indirect effects of neriifolin on neuroprotection, but these seem 
unlikely in view of our in vitro observations that cardiac glycosides inhibit stress-induced 
autophagy and autosis in a cell autonomous manner.  
 It is noteworthy that — during cerebral hypoxia or ischemia — the brain releases an 
endogenous form of cardiac glycoside (ouabain or endobain) that inhibits Na+,K+-ATPase 
(33). Thus, by releasing its own inhibitor of Na+,K+-ATPase in response to hypoxia-
ischemia, the neonatal brain may have developed an important mechanism to reduce 
autophagy and cell death by autosis. A broader question is whether basal levels of 
endogenous cardiac glycosides may serve as a naturally occurring “brake” which 
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functions in multiple mammalian tissues to maintain autophagy at physiological levels 
that promote cell survival, rather than at pathological levels that promote cell death.  
 
 
MATERIALS AND METHODS 
 
Cell Culture. HeLa cells were obtained from ATCC (American Type Culture Collection). 
Information on the source of wild-type, Ripk3-/-, Ripk1-/-;Ripk3-/-, and Bax-/-;Bak-/- MEFs, 
Atg5flox/flox and Atg5flox/flox-LysM-Cre BMDMs, and U2OSTetR, U2OSTetR/shATG14, and 
U2OSTetR/shATG13, other cells used in this study, and culture conditions is provided in  
the  SI Materials and Methods.    
 
Autophagy-Inducing Peptides. Tat-Scrambled (YGRKKRRQRRRGGVGNDFFINHE 
TTGFATEW), Tat-Beclin 1 (YGRKKRRQRRRGGTNVFNATFEIWHDGEFGT), and 
Tat-vFLIP α2 (D-retro-inverso form, RRRQRRKKRGYGFVNLLFLVVE) (14) were 
synthesized and administered to cells as described (13).  
 
Antibodies and siRNAs. See SI Materials and Methods for details of antibodies and 
siRNAs used in this study. 
 
Cell Death Assays.  See SI Materials and Methods for details of trypan blue staining, 
Sytox Green staining, CellTiter-Glo assays, propidium iodide staining, active caspase 3 
detection, TUNEL staining, DNA fragmentation assays, and clonogenic survival assays.   
 
Microscopy studies. Live cell imaging was performed using a Deltavision microscope in 
the UT Southwestern Live Cell Imaging Core. Immunofluorescent microscopic images 
were captured using a Zeiss Axioplan 2 microscope using staining protocols described in 
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the SI Materials and Methods. Immunofluorescence and immunohistochemical staining 
of rat brain sections was performed following hypoxia-ischemia as described in the SI 
Materials and Methods. Electron microscopy was performed on cells as described (13) 
and images were captured using a JEOL 1200 EX II Electron Microscope (UT 
Southwestern Electron Microscopy Core). Electron microscopy was performed on rat 
hippocampal sections as described (17) and sections were visualized using a Philips 
CM100 transmission electron microscope (Electron Microscopy Facility at the University 
of Lausanne). See SI Materials and Methods for information about Correlative Light 
Electron Microscopy (CLEM) experiments. 
 
High-Throughput Chemical Screening. High-throughput chemical screening to identify 
inhibitors of Tat-Beclin 1-induced autosis was performed using CellTiter-Glo 
luminescent cell viability assays (Promega) with ~5,000 known bioactive compounds 
with characterized mechanisms, drawn from commercially available libraries: the 
Prestwick Chemical Library of FDA-approved drugs (Prestwick Chemical); LOPAC 
(Sigma-Aldrich); and the KBio3 library which includes the Spectrum (Microsource 
Discovery Systems), Biomol-NT (Biomol, now Enzo Life Sciences), and ICCB Known 
Bioactives (Enzo Life Sciences) collections. Details of the screening techniques and 
analyses are provided in the SI Materials and Methods. 
 
Autophagy Analyses. Autophagy was assessed by fluorescent microscopic 
quantification of GFP-LC3 puncta in HeLa/GFP-LC3 cells as described (13), by 
immunostaining to detect LC3 and LAMP1 in rat brains, by western blot analysis of LC3 
and p62 of cultured cells, and by electron microscopic analysis of cultured cells and rat 
brains.   
 
 23 
Rat model of neonatal cerebral hypoxia-ischemia. Neonatal rat cerebral hypoxia-
ischemia experiments were performed as described (17). Immediately after carotid artery 
occlusion, rat pups were injected intraperitoneally with either neriifolin (0.25 mg/kg 
diluted in 0.5%ethanol/PBS) (Sigma, S961825) or vehicle (0.5%ethanol/PBS). See SI 
Materials and Methods for details. All experiments were performed in accordance with 
the Swiss Laws for the protection of animals and were approved by the Vaud Cantonal 
Veterinary Office.  
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FIGURE LEGENDS 
 
Fig 1. Tat-Beclin 1 induces autophagy-dependent cell death. (A) Western blot of LC3 
and p62 in HeLa cells treated with Tat-Scrambled (T-S) or Tat-Beclin 1 (T-B) peptides 
for 5 h. (B) Cell death of HeLa cells treated T-S or T-B for 5 h. (C) Representative 
images of Sytox Green staining of HeLa cells treated with T-S or T-B (20 µM, 5 h). Scale 
bar, 50 µm. (D-E) Representative images (D) and quantification (E) of clonogenic cell 
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survival of HeLa cells treated with T-S or T-B (20 µM, 5 h). (F) Death of HeLa cells 
treated with T-B (20 µM, 5 h) + 10 mM 3-MA, 100 µM z-VAD, or 100 µM necrostatin-1 
(Nec-1). (G) Clonogenic survival of HeLa cells treated with T-B (20 µM, 4 h) + 10 mM 
3-MA. (H) Cell death in siRNA-transfected HeLa cells treated with T-S or T-B (20 µM, 5 
h). (I) Clonogenic survival of siRNA-transfected HeLa cells treated with T-B (20 µM, 
3h). (J) Cell death of doxycycline (Dox)-inducible U2OS/TR, U2OS/shATG13 and 
U2OS/shATG14 cells + Dox (1 µg/ml) for 5 days prior to treatment with T-S or T-B (20 
µM, 6 h). (K) Clonogenic survival of doxycycline (Dox)-inducible U2OS/TR, 
U2OS/shATG13 and U2OS/shATG14 cells + Dox (1 µg/ml) for 5 days prior to treatment 
with T-B (25 µM, 5 h). For B and E-K, bars represent mean + SEM and similar results 
were observed in three (B, F-K) or 5 (E) independent experiments. For E, G, I, and K, the 
number of colonies in untreated controls was standardized as 100%. NS, not significant; 
**P<0.01; ***P<0.001; t-test. See also Fig. S1. 
 
Fig. 2. Tat-Beclin 1-induced cell death does not require the apoptotic or necroptotic 
machinery. (A-B) Cell death (A) and clonogenic survival (B) of wild-type and Bax-/-; 
Bak-/- MEFs treated with peptide (5 h). (C-D) Cell death (C) and clonogenic survival (D) 
of wild-type, Ripk1+/+; Ripk3-/- and Ripk1-/-; Ripk3-/- MEFs treated with peptide (20 µM, 5 
h). In (B) and (D), the number of colonies of Tat-Scrambled-treated cells was 
standardized as 100%. (E) Western blot of cleaved caspase 3 and cleaved PARP in HeLa 
cells treated with 20 µM Tat-Scrambled, 20 µM Tat-Beclin 1, 1 µM staurosporine + 100 
µM Z-VAD-FMK (z-VAD), or 32 mM H2O2 for 5 h. Asterisk denotes a cross-reacting 
band. (F) Representative images of cleaved caspase 3 staining in HeLa cells treated with 
20 µM Tat-Beclin 1 or 1 µM staurosporine for 5 h. Scale bar, 50 µm. For A-D, bars 
represent mean + SEM of triplicate samples and similar results were observed in three 
independent experiments. NS, not significant; ***P<0.001; t-test. See also Fig. S2. 
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Fig. 3. Morphological features of Tat-Beclin 1-induced autosis. (A) Representative 
live-cell imaging of HeLa cells treated with 25 µM Tat-Beclin 1 for 5 h (Video S1, times 
shown as hh:mm). Black arrow denotes released intracellular components from a 
ruptured cell membrane and white arrow denotes a perinuclear space between the inner 
nuclear membrane and cytoplasm at a region of nuclear concavity. Scale bar, 10 µm. (B) 
Representative images of mitochondrial (Tom20), ER (PDI), late endosome/lysosome 
(LAMP1), and nuclear lamin A/C staining in HeLa cells treated with Tat-Scrambled (T-S) 
or Tat-Beclin 1 (T-B) (20 µM, 5 h). Scale bar, 20 µm. (C) Electron microscopic analysis 
of HeLa cells treated with peptide (20 µM, 5 h). White arrows show dilated and 
fragmented ER; black arrows show regions where the perinuclear space has swollen and 
contains clumps of cytoplasmic material. Scale bars, 1 µm. See also Figure S3. 
 
Fig. 4. Starvation induces autosis. (A) Representative images of active caspase 3 
staining in HeLa cells 48 h after starvation (HBSS). Middle, active caspase 3-positive 
floating cells with rounded nuclei. Right, active caspase 3-negative adherent cell with 
concave nucleus and swollen perinuclear space. Scale bar, 20 µm. (B) Representative 
image of a Sytox Green-positive adherent HeLa cell (top) and abnormal nuclear lamin 
A/C staining in an adherent HeLa cell (bottom) 48 h after starvation. Scale bars, 10 µm. 
(C-D) Representative images (C) and quantitation (D) of GPF-LC3 dots 
(autophagosomes) in HeLa/GFP-LC3 cells (>50 cells analyzed per sample) grown in 
normal medium or in floating and adherent HeLa/GFL-LC3 cells 6 h after starvation. 
Scale bar, 10 µm. (E) Upper row, electron microscopic images of a Phase 1 substrate-
adherent HeLa cell 6 h after starvation. Lower row, correlative light-electron microscopy 
images of a Phase 2 substrate-adherent HeLa cell with concave nucleus and swollen 
perinuclear space (PNS) (arrow) 8h after starvation. Lower left, phase contrast 
microscopy; lower middle and lower right, electron microscopy of same cell. Black arrow 
in right lower panel shows outer nuclear membrane (ONM) and white arrow shows inner 
 28 
nuclear membrane (INM). Scale bars, 1 µm. (F) Representative images of a Sytox Green-
positive adherent primary murine BMDM and MEF 48 h after starvation. Scale bar, 10 
µm. (G) Clonogenic survival of siRNA-transfected adherent HeLa cells starved for 48 h. 
NC, non-targeting control siRNA. (H) Clonogenic survival of doxycycline (Dox)-
inducible adherent U2OS/TR and U2OS/shATG14 cells + Dox treatment (1 µg/ml) for 5 
days prior to starvation for 72 h. (I) Clonogenic survival of adherent BMDMs (two mice 
per genotype; Atg5fl/fl; Lyz-Cre- and Atg5fl/fl; Lyz-Cre+ littermates) starved for 72 h. For 
D and G-I, bars represent mean + SEM of triplicate samples and similar results were 
observed in three independent experiments. For A-C and F, arrows denote concave 
nucleus and swollen perinuclear space. NS, not significant; **P<0.01; ***P<0.001; t-test. 
See also Fig. S4. 
 
Fig. 5. Morphological features of cerebral hypoxia-ischemia-induced autosis. 
Electron microscopic analysis of dying neurons in hippocampal region CA3 in brains of 
7-day-old rats 24 h after exposure to cerebral hypoxia-ischemia. Arrows show regions 
where the perinuclear space is swollen and contains clumps of cytoplasmic material. 
Scale bars, 1 µm. N, nucleus, PNS, perinuclear space; INM, inner nuclear membrane; 
ONM, outer nuclear membrane; ER, endoplasmic reticulum; GA, Golgi apparatus; M, 
mitochondrion. 
 
Fig. 6. Cardiac glycosides rescue autosis. (A) Ranked distribution of z-scores for each 
compound in primary chemical screen (Table S1) for inhibitors of Tat-Beclin 1-induced 
cell death. Thirty-six top hits with z ≥ 3.0 (Table S2) were selected for a secondary 
screen (Table S3). (B) Comparison of Compound Set Enrichment Analysis (CSEA) of 
cardiac glycosides in the primary autosis screening with compound sets of specific 
autophagy, necrosis, or apoptosis inducers. NES: normalized enrichment score. p = 
permutation P-value for the NES compared to a null distribution. Red-blue vertical bars 
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represent list of screened compounds, ranked according to z-score (greatest rescue of 
autosis at top). Each horizontal line indicates where a specific compound falls within 
ranked compound list. (C) Clonogenic survival of HeLa cells treated with Tat-Beclin 1 
(20 µM, 5 h) + 5 µM digoxin, digitoxigenin or strophanthidin. The number of colonies of 
untreated cells was standardized as 100%. (D) Clonogenic survival of HeLa cells treated 
with 20 µM Tat-Scrambled, 20 µM Tat-Beclin 1, or 5 µM Tat-vFLIP α2 for 5 h + 5 µM 
digoxin. The number of colonies of cells treated with Tat-Scrambled without digoxin was 
standardized as 100%. (E-F) Clonogenic survival of HeLa cells starved for 48 h + 10 nM 
digoxin (E) or 1 nM neriifolin (F). (Nanomolar concentrations were used as toxicity of 
digoxin and neriifolin was observed during starvation with micromolar concentrations.) 
(G) Representative images of mitochondrial (Tom20), ER (PDI), late 
endosome/lysosome (LAMP1), and nuclear lamin A/C staining in HeLa cells treated with 
20 µM Tat-Scrambled or Tat-Beclin 1 + 5 µM digoxin for 5 h. Scale bar, 20 µm. (H) 
Representative electron microscopic images of a HeLa cell treated with 20 µM Tat-
Beclin 1 + 5 µM digoxin (5 h). Scale bar, 1 µm. (I) Quantitation of GFP-LC3 dots (>100 
cells analyzed per sample) in HeLa/GFP-LC3 cells treated with 20 µM Tat-Beclin 1 or 
starved in HBSS for 2 h + 0.1 µM digoxin and/or 20 nM bafilomycin A1. For C-F and I, 
bars represent mean + SEM of triplicate samples and similar results were observed in 
three independent experiments. NS, not significant; *P<0.05; **P<0.01; ***P<0.001; t-
test. See also Fig. S5, tables S1-S4. 
  
Fig. 7. Na+,K+-ATPase regulates autosis. (A) Quantitation of GFP-LC3 dots (>100 cells 
analyzed per sample) in HeLa/GFP-LC3 cells 72 h after transfection with indicated 
siRNA and treatment with Tat-Beclin 1 (20 µM, 2h) or starvation (HBSS, 2 h) + 20 nM 
bafilomycin A1. (B) Cell death measurement of HeLa cells transfected with indicated 
siRNA for 72 h, and then treated with Tat-Scrambled (20 µM), Tat-Beclin 1 (20 µM), or 
Tat-vFLIP α2 (5 µM) for 6 h. (C) Clonogenic survival of HeLa cells transfected with 
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indicated siRNA for 72 h and then treated with Tat-Scrambled or Tat-Beclin 1 (20 µM, 5 
h). Shown are the percentage of colonies in Tat-Beclin 1- vs. Tat-Scrambled-treated cells 
for each siRNA. (D) Clonogenic survival of adherent HeLa cells transfected with 
indicated siRNA for 72 h, and then starved for 48h. Clonogenic survival of control 
siRNA transfected cells in starvation conditions relative to normal medium standardized 
as 100%. For A-D, bars represent mean + SEM of triplicate samples and similar results 
were observed in three independent experiments. NS, not significant;*P<0.05; **P<0.01; 
***P<0.001; t-test. See also Fig. S6. 
 
Fig. 8. Neonatal hypoxic-ischemic brain damage and hippocampal CA3 region 
autophagy and autosis are reduced by treatment with the cardiac glycoside, 
neriifolin. (A) Representative Nissl-stained coronal sections through the brain showing 
the neuroprotective effect of neriifolin (bottom) as compared to vehicle (top) one week 
after HI. Scale bar, 1 mm. (B) Volumes of intact tissue ipsilaterally as compared to 
contralaterally one week after neonatal cerebral HI and indicated treatment. Values are 
mean ± SD (n=6 for neriifolin and n=9 for vehicle). ***P<0.001; Welch’s ANOVA test. 
(C) Representative confocal microscopy images of LC3 dots (red) and LAMP1 dots 
(green) in CA3 hippocampal neurons after 24h HI and indicated treatment or sham 
operation. NeuN (green) and MAP2 (red) are neuronal markers. Hoechst staining (blue) 
shows cell nuclei. Scale bars, 20 µm. (D-E) Representative LC3 immunoblots (D) and 
quantification of LC3-II/tubulin levels (E) from immunoblots of hippocampi of rats 
subjected to HI. Values are mean ± SD (n=6 for neriifolin and n=9 for vehicle). NS, not 
significant; *P<0.05; **P<0.001; Kruskal-Wallis test. (F) Electron microscopic analysis 
of neriifolin effects in hippocampal region CA3 of 7-day-old rats 24 h after HI. PNS, 
perinuclear space; INM, inner nuclear membrane; ONM, outer nuclear membrane; N, 
nucleus; ER, endoplasmic reticulum; M, mitochondrion. Scale bars, 1 µm.  
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SUPPLEMENTARY INFORMATION 
 
SI MATERIALS AND METHODS 
 
Cell Culture. HeLa, MCF7, IMR90, Rat2 and NIH3T3 cells were obtained from ATCC 
(American Type Culture Collection). HCC827 and H1975 cells were obtained from Dr. 
John Minna (UT Southwestern Medical Center). U2OS cells were obtained from Dr. 
Sandra Zinkel (Vanderbilt University School of Medicine) (1). Primary wild-type, Ripk3-
/- and Ripk1-/-; Ripk3-/- MEFs were obtained as described (2, 3) from day e12 embryos. 
E1A-Ras transformed wild-type and Bax-/-; Bak-/- MEFs (4) were obtained as previously 
described (5). U2OSTetR (U2OS/TR) and doxycycline-inducible U2OS cells expressing 
shATG14/Barkor (6) were obtained from Dr. Qing Zhong (University of California 
Berkeley). Doxycycline-inducible U2OS cells expressing shATG13 (7) were obtained 
from Dr. Xiaodong Wang (National Institute of Biological Sciences, Beijing). Femurs 
from Atg5fl/fl; Lyz-Cre- and Atg5fl/fl; Lyz-Cre+ littermate mice (8) were provided by Dr. 
Herbert Virgin (Washington University School of Medicine, St. Louis, Missouri) and 
bone marrow derived macrophages (BMDMs) were cultured as described.   
 HeLa, MCF7, U2OS and NIH3T3 cells were cultured in DMEM supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. MEFs were cultured in 
DMEM supplemented with 20% FBS, 1×MEM non-essential amino acids, 1% 
penicillin/streptomycin and 0.1 mM β-mercaptoethanol. IMR90 and Rat2 cells were 
cultured in DMEM supplemented with 15% FBS, 1×MEM non-essential amino acids, 1% 
penicillin/streptomycin and 0.1 mM β-mercaptoethanol. HCC827 and H1975 cells were 
cultured in RPMI medium supplemented with 10% FBS and 1% penicillin/streptomycin. 
Doxycycline-inducible U2OS cells were cultured in Tet-approved FBS (Clontech, 
#631101) and then treated with 1 µg/ml doxycycline (Clontech, #631311) for 5 days. For 
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starvation experiments, cells were cultured in Hanks Balanced Salt Solution (HBSS) 
(Sigma, #H4641) for the indicated time period. 
 
Chemical Reagents and Antibodies. The chemical reagents used in this study were: 
staurosporine (Fisher Scientific, #A380014C250), hydrogen peroxide (Sigma, #H1009), 
3-methyladenine (Sigma, #M9281), z-VAD-FMK (Enzo Life Sciences, #ALX-260-020-
M005), necrostatin-1 (Enzo Life Sciences, #BML-AP309), digoxin (Sigma, #D6003), 
digitoxigenin (Sigma, #D9404), strophanthidin (Sigma, #S6626), neriifolin (Sigma, 
#S961825), suramin (Sigma, #2671), NF 023 (Sigma, #N8652), niclosamide (Sigma, 
#N3510), quercetin (Sigma, #0020-05-95), myricetin (Sigma, #M6760), luteolin (Sigma, 
L9283), GP4G (Sigma, #D1262), nitrendipine (Sigma, #N144), miconazole (Sigma, 
#M3512), sulconazole (Sigma, #S9632), etoposide (Sigma, #E1383) and bafilomycin A1 
(Sigma, #B1793). 
The antibodies used for immunoblot analyses include: anti-LC3 (Novus Biologicals, 
#NB100-2220, 1:400 dilution for cell lysates; 1:1000 dilution for hippocampal lysates), 
anti-p62 (Abnova, #H00008878-M01, 1:2,000 dilution), anti-cleaved caspase-3 (Asp175) 
(Cell Signaling, #9661, 1:1,000 dilution), anti-cleaved PARP (Asp214) (Cell Signaling, 
#9541, 1;1,000 dilution), anti-Na+,K+-ATPase α1 subunit (Santa Cruz Biotechnology, 
#sc-21712, 1:100 dilution), anti-Actin (Santa Cruz Biotechnology, #sc-47778, 1:20,000 
dilution), anti-ATG13 (Sigma, #SAB4200100, 1:500 dilution), anti-ATG14 (MBL, 
#PD026, 1:200 dilution), anti-ATG5 (Novus Biologicals, #NB110-53818, 1:500 dilution), 
anti-Beclin 1 (Santa Cruz Biotechnology, #sc-11427, 1:500 dilution), anti-ATG7 (Sigma, 
#A2856, 1:500 dilution), anti-cytochrome c (Santa Cruz Biotechnology, #sc-13156, 
1:1,000 dilution), and anti-α-tubulin (Santa Cruz Biotechnology, #sc-8035; 1:2000 
dilution).  
The antibodies used for immunofluorescence analyses of cultured cells include: anti-
Tom20 (Santa Cruz Biotechnology, #sc-11415, 1:2,000 dilution), anti-PDI (Cell 
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Signaling, #3501, 1:200 dilution), anti-lamin A/C (Santa Cruz Biotechnology, #sc-6215, 
1:200 dilution), and anti-LAMP1 (Santa Cruz Biotechnology, #sc-20011, 1:200 dilution). 
Active caspase 3 was detected by immunofluorescence using anti-cleaved caspase-3 
(Asp175) (Cell Signaling, #9661, 1:400 dilution) antibody.   
The antibodies used for immunohistochemical analyses of rat brain sections include: 
anti-microtubule associated protein 2 rabbit (Millipore, #AB5622; 1:200 dilution), anti-
NeuN (Millipore, #MAB377; 1:200 dilution) and anti-LAMP1 (Calbiochem, #428017; 
1:200 dilution). Anti-microtubule-associated protein 1 light chain 3 (LC3) was a gift from 
Professor Y. Uchiyama (Tokyo, Japan; 1:2,000 dilution).  
 
Western Blot Analyses. For cultured cells, cell lysates were prepared by sonication in 
PBS buffer containing 1% NP-40, protease inhibitor cocktail (Roche Applied Sciences) 
and halt phosphatase inhibitor cocktail (Thermo Scientific). Protein concentrations of cell 
lysates were determined using the Bio-Rad Protein Assay (Bio-Rad, #500-0006). Proteins 
were separated by SDS-PAGE, transferred onto nitrocellulose membranes, and subjected 
to western blot analysis with the indicated antibodies.  
For immunoblot analysis of tissue samples, the whole hippocampus was collected in 
lysis buffer (20 mM HEPES, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 2.5 mM EGTA, 0.1 
mM dithiothreitol, 50 mM NaF, 1 mM Na3VO4, 1% Triton X-100 (reagents from Sigma-
Aldrich), and a protease inhibitor cocktail (Roche)) 24 h after cerebral hypoxia-ischemia. 
Proteins were separated by SDS-PAGE, transferred onto nitrocellulose membranes and 
analyzed by immunoblotting. A blocking solution containing 0.1% casein and 0.1% 
Tween was used for dilution of primary antibodies. Protein bands were visualized using 
the Odyssey Infrared Imaging System (LI-COR). Odyssey v1.2 software (LI-COR) was 
used for densitometric analysis. Optical density values were normalized with respect to 
tubulin and expressed as a percentage of values obtained for sham-operated rat pups 
(100%). 
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siRNA Transfection. siRNAs targeting human beclin 1 
(GAGAGGAGCCAUUUAUUGA, CUAAGGAGCUGCCGUUAUA, 
GGAACUCACAGCUCCAUUA and GAUACCG ACUUGUUCCUUA) were purchased 
from Thermo Scientific on-target plus SMARTpool (L-010552-00-0005). siRNA 
targeting human ATG7 (GGGUUAUUACUACAAUGGUGUU) was purchased from 
Dharmacon. Non-targeting siRNA was purchased from Thermo Scientific (D-001210-02-
20). siRNAs targeting the human Na+, K+-ATPase α1-subunit (No. 1: 
CUCGCUCACUGGUGAAUCA; No. 2: GAUUCGAAAUGGUGAGAAA; No. 3: 
CAUCCAAGCUGCUACAGAA) were purchased from Invitrogen (#4390824). siRNA 
targeting the α1-subunit of mouse Na+,K+-ATPase (GGAUGAACUCCAUCGUAAA) 
was purchased from Invitrogen (#4390824). siRNA was transfected using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instructions. After 72 h of transfection, 
cells were treated as described. 
 
Immunofluorescence Staining of Cultured Cells. Cells were fixed using a 3% 
paraformaldehyde/2% sucrose solution and permeabilized with a Triton X-100 solution 
(0.5% Triton X-100, 20 mM HEPES pH7.4, 50 mM NaCl, 3 mM MgCl2, 300 mM 
sucrose) or fixed using ice-cold methanol according to the manufacturer’s instructions. 
The subcellular localization of organelle markers was detected by immunofluorescent 
staining and microscopy. For deconvolution analysis, cell images were captured using a 
Zeiss Axio Imager Z2 microscope and images were processed with AutoQuant X 2.2.2 
and Imaris x64 7.5.0 software. 
 
Correlative Light Electron Microscopy. For Correlative Light Electron Microscopy 
(CLEM), 1.6 x 105 cells were plated on a glass-bottom microwell dish (MatTek, #P35G-
2-14-C-GRID) and cultured in HBSS for 8 h prior to fixation and EM analysis as 
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described in the main text. Brightfield images were captured using a Deltavision 
microscope in the UT Southwestern Live Cell Imaging Core. 
  
Immunohistochemical and Immunofluoresence Analyses of Rat Brain Sections. For 
immunoperoxidase labelling of rat brain sections, quenching of endogenous peroxidases 
was first done in 0.3% H2O2 in methanol for 20 min and pre-incubation in 15% serum 
and 0.1% Triton X-100 in PBS for 45 min. Sections were then incubated overnight with 
the primary antibody in 1.5% serum and 0.1% Triton in PBS followed by 2 h with the 
biotinylated secondary antibody (Jackson Immunoresearch) and detected using an avidin-
biotin-peroxidase kit (VECTASTAIN Elite ABC Kit Vector, PK-6200) for 2 h at room 
temperature and incubation with diaminobenzidene (DAB, Roche, 11718096001) 
substrate solution. Sections were then dehydrated in graded alcohols and mounted in 
Eukitt mounting medium.  
For immunofluorescence labeling, sections were first pre-incubated for 45 min in 15% 
serum and 0.1% Triton X-100 in PBS and then incubated overnight at 4°C with the 
primary antibody in 1.5% serum and 0.1% Triton in PBS, and then incubated for 2 h in 
fluorochrome-coupled secondary antibody (Alexa Fluor 488 or Alexa Fluor 594 from 
Molecular Probes) at room temperature. The sections were then rinsed in PBS and 
mounted with FluorSave (Calbiochem, #345-789-20) with or without Hoechst nuclear 
staining. An LSM 710 Meta confocal microscope (Carl Zeiss) was used for confocal laser 
microscopy. Confocal images were displayed as individual optical sections. For double-
labeling, immunoreactive signals were sequentially visualized in the same section with 
two distinct filters, with acquisition performed in separated modes. Images were 
processed with LSM 710 software and mounted using Adobe Photoshop. 
 
Cell Death Assays.  The percentage of Trypan blue-positive cells was counted using 
Trypan blue (Bio-Rad #145-0021) for triplicate samples per condition with a minimum of 
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100 cells per sample. For Sytox Green staining, cells were cultured in Lab-Tek chamber 
slides (Thermo Scientific) and Sytox Green (100 nM) (Invitrogen, S7020) was added in 
the medium for one h following various treatments. After washing once with PBS, Sytox 
Green-positive cells were visualized using a Zeiss Axioplan 2 microscope, and counted 
for triplicate samples per condition with a minimum of 100 cells per sample. CellTiter-
Glo assays were performed using CellTiter-Glo® Luminescent Cell Viability Kit 
according to the manufacturer’s instructions (Promega, G7572). TUNEL staining was 
performed to detect apoptotic nuclei using the ApopTag Peroxidase In Situ Apoptosis 
Detection Kit according to the manufacturer’s instructions (Millipore, #S7100). DNA 
ladder assays were performed using the genomic DNA purified from HeLa cells treated 
with 20 µM Tat-Scrambled, 20 µM Tat-Beclin 1 or 1 µM staurosporine. Genomic DNA 
was purified by phenol/chloroform/isoamyl alcohol and precipitated by isopropyl alcohol. 
DNA concentration was measured by determining the OD260 and 1 µg DNA was loaded 
in each well. Annexin V-Propidium iodide staining, active caspase 3 detection, and 
clonogenic survival assays were performed as described below.   
 
Flow Cytometry. For active caspase detection, HeLa cells were stained using the APO 
LOGIX Carboxyfluoroscein Caspase Detection Kit (Cell Technology Inc, #FAM100-1). 
Briefly, cells were labeled with carboxyfluorescein (FAM)-VAD-FMK added to the 
culture medium for one additional h following various treatments. Cells were trypsinized 
and stained with propidium iodide according to the manufacturer’s instructions. Cell 
population data were acquired using a FACS Calibur (UT Southwestern Flow Cytometry 
Core) and analyzed using Flowjo 8 software. 
For Annexin V staining, HeLa cells were trypsinized and stained with AnnexinV-
FITC (BioVision, #1101, 1:500 dilution) and 3.125 µg/ml propidium iodide (Roche, 
#11348639001) in binding buffer (10 mM HEPES/NaOH, 150 mM NaCl, 5 mM KCl, 1 
mM MgCl2, 2 mM CaCl2, pH 7.4) at room temperature for 15 min. Cell population data 
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were acquired using a FACS Calibur (UT Southwestern Flow Cytometry Core) and 
analyzed using Flowjo 8 software. 
 
Clonogenic Survival Assays. Clonogenic survival assays were performed as described 
(9). Briefly, 1,000 cells/well were plated overnight in a 6-well plate. After treatment with 
Tat-Beclin 1 for the indicated time period, cells were allowed to recover in regular 
culture medium lacking any peptide for 4-10 days. To quantitate clonogenic survival, 
cells were washed once with PBS, fixed and stained with 6% glutaraladehyde and 0.5% 
crystal violet for 2 h. To evaluate clonogenic survival of adherent cells following 
starvation, cells were plated in a 6-well plate and cultured O/N to reach 80-90% 
confluency, and then cultured in HBSS for the indicated time period. After washing three 
times with PBS, cells were allowed to recover in normal medium for 7-10 days and 
similar methods were used to quantitate clonogenic survival. 
 
In vitro Cytochrome c Release Assay. Mouse mitochondria were isolated from the 
livers of wild-type C57/BL6 (8-10-week-old) mice as described (10). Fresh 
mitochondrial pellets were resuspended in buffer (10 mM HEPES, 250 mM sucrose, 1 
mM ATP, 5 mM succinate, 0.08 mM ADP, 1 mM DTT, 2 mM K2HPO4, pH 7.4), and 50 
µg was incubated with either Tat-Scrambled or Tat-Beclin 1 in 100 µl buffer at 37oC for 
1 h. The supernatants and pellets were isolated by 10,000×g centrifugation at 4oC for 10 
min. Eighty µl of each supernatant was boiled in 5× Laemmli buffer. The pellets were re-
suspended with 80 µl buffer and boiled in 5× Laemmli buffer.  
 
Peptide Entry Assay. N-terminal biotinylated Tat-Beclin 1 peptide (>95% purity as 
determined by RP-HPLC) was synthesized as described (11). For the peptide entry assay, 
cells were treated with 20 µM biotinylated Tat-Beclin 1 for 30 min, fixed with 4% 
paraformaldehyde at room temperature for 10 min, and permeabilized with Triton X-100 
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solution (0.5% Triton X-100, 20 mM HEPES pH7.4, 50 mM NaCl, 3 mM MgCl2, 300 
mM sucrose) for 5 min on ice. After staining with Alexa Fluor 488-conjugated 
streptavidin for 1 h, more than 400 cells were imaged using a Zeiss Axioplan 2 imaging 
microscope. Cells showing a typical intracellular staining pattern of Alexa Fluor 488 
signal were counted as biotin-positive cells.  
 
RT-PCR. Total RNA from 2×105 HeLa cells was extracted and purified by an RNeasy 
Mini Kit (Qiagen) and 2 μg of RNA was subjected to reverse-transcription (Invitrogen) to 
obtain cDNA. Semi-quantitative RT-PCR was performed using the following primers: 
actin (5'- CATGTACGTTGCTATCCAGGC-3', 5'-CTCCTTAATGTCACGCACGAT-3'), 
LC3B (5'-CATGCCGTCGGAGAAGACCTTC-3', 5'-
GTGTCCGTTCACCAACAGGAAG-3'), and p62 (5'-
GACTACGACTTGTGTAGCGTC-3', 5'-AGTGTCCGTGTTTCACCTTCC-3'). 
 
Compound Screening and Data Analysis. For chemical compound screening, 1,500 
HeLa cells/well were plated in 384-well plates (Corning, #3707) using a Multidrop 
instrument (MTX Lab System, Multidrop 384). The culture medium was aspirated and 
replaced with acidified Opti-MEM medium. Mock-treated (DMSO) cells and Tat-Beclin 
1-treated cells with DMSO were included in each plate as standard controls. Compounds 
were added in triplicate using a Beckman FX liquid handler and incubated at 37oC/5% 
CO2 for 30 min. Twenty µM Tat-Beclin 1 was then added to each well and incubated at 
37oC/5% CO2 for 5 h. The culture medium was aspirated off, and the measurement of 
cellular ATP levels was performed by adding 35 µl CellTiter-Glo solution (Promega, 
#G7573) per well and subsequent detection using an EnVision multimode plate reader. 
Compounds were assembled from commercially available libraries of FDA-approved 
drugs and known bioactive drugs with characterized mechanisms: Prestwick Chemical 
Library of FDA-approved drugs (Prestwick Chemical); LOPAC (Library of 
 9 
Pharmacologically Active Compounds; Sigma-Aldrich); and the KBio3 library which 
includes the Spectrum Collection (Microsource Discovery Systems), Biomol-NT (Biomol, 
now Enzo Life Sciences), and ICCB Known Bioactives (Enzo Life Sciences). 
 Each compound was screened in triplicate. Using established data analysis pipelines 
(12, 13), replicate raw luminescence values were normalized, weighted for 
reproducibility across replicates, and converted to z-scores (where z = (weighted 
compound score - mean DMSO score) / (standard deviation of DMSO score). The 
Prestwick library was screened and analyzed independently at two different institutions 
(UT Southwestern, Massachusetts General Hospital) and the cardiac glycosides were 
strong hits in both screens, showing strong internal reproducibility. 
 For analysis of the Prestwick library compounds screened at the UT Southwestern 
high-throughput screening facility, experimental results obtained from EnVision 
multimode plate reader were analyzed using Genedata Screener® System (version 10). 
For each plate, the raw data values for all wells were normalized using Equation 1:  
Normalized Values = Raw Values-Median of Neutral Controls
Median of Stimulatory Controls-Median of Neutral Controls
×100           
Then normalized values were corrected using Equation 2: 
Corrected Values = Normalized Values
Correction Factor
  
, where the correction factor of a plate is calculated based on Genedata Screener® 
proprietary pattern detection algorithms. As each compound was assayed in triplicate in 
the screen, the three corrected values were condensed to a single value (condensed 
activity) using the "Robust Condensing" method in Genedata Screener®, which is the 
most representative single value of the triplicates. In general, the triplicates were pre-
condensed into a pair of values: Values(X,Y) = (Median of Triplicates m) + dispersion, 
where  Dispersion = Median (�X1-m�, �X2-m�, �X3-m�). The less X and Y differ (ǀX - Yǀ), 
the better the data quality. For data points with ǀX - Yǀ ≤ 30% activity, the median of X 
and Y was used as the condensed activity, which is also the median of the triplicate 
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measurements. Otherwise, a condensing function Max(X, Y) was used for determining the 
condensed activity.  
Robust z-Score was then calculated for each compound using Equation 3: 
Robust Z-Score = Condensed Activity-Median of Neutral Controls
Robust Standard Deviation of Neutral Controls
                                          
, where robust standard deviation is the standard deviation calculated using median of 
neutral controls instead of the mean of neutral control. Compounds tested later were 
ranked by Robust z-Score, and 36 compounds with Robust z-Scores higher than 3.0 were 
cherry picked and evaluated in confirmatory assays. Experimental results of the cherry-
picked compounds were normalized using Equation 4: 
Normalized Values = Raw Values-Median of Neutral Controls
Median of Neutral Controls
×100                                                
Then for each cherry-picked compound, the corrected value, condensed activity, and 
Robust z-Score were calculated using Equation 2 and Equation 3. More details of data 
analysis methods could be found in Genedata Screener® user documentation (14) or upon 
request.  
For analysis of compounds from other libraries in screens performed at the 
Massachusetts General Hospital, replicate raw luminescence values for each compound 
were converted to a z-score using a standard analytic pipeline (12); in brief, z = (mean 
compound luminescence – mean DMSO luminescence) / (standard deviation of DMSO 
luminescence).  
 Compound Set Enrichment Analysis (CSEA) (12) utilized the GSEA module of the 
GenePattern software suite (broadinstitute.org/cancer/software/genepattern) (15) using 
standard settings for pre-ranked lists. CSEA is based on Gene Set Enrichment Analysis 
(16), which is widely used to identify sets of functionally related genes that are 
coordinately up- or down-regulated. CSEA calculates a permutation P-value for a given 
compound set using an established method, by randomly generating 1000 compound sets 
with the same number of compounds as the query set, and generating a null distribution 
from the normalized enrichment scores for these 1000 permutated compound sets. CSEA 
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analysis used ranked screening results from the Prestwick, Spectrum, Biomol and ICCB 
collections. In addition to cardiac glycosides, CSEA compound sets were drawn from the 
overlap between our screened compounds and those annotated by Shen et al. as 
specifically inducing apoptosis (Cluster-III), or necrosis (Cluster-IV) (17). In addition, 
the “Broad Autophagy Toolkit” is a collection of autophagy inducers that was compiled 
from the literature (18-25) and comprised the autophagy inducers in the CSEA compound 
set. 
 
Neonatal Hypoxia-Ischemia Model. Hypoxia-ischemia (HI) was performed in 7-day-
old male rats (Sprague Dawley of 16-19 g, from Janvier, France) according to the Rice-
Vannucci modification of the Levine procedure (26). The rat pups were anesthetized with 
3% isoflurane. The right common carotid artery was isolated, double-ligated and cut. Just 
after carotid occlusion, neriifolin (0.22 mg/kg diluted in 0.5% ethanol/PBS) (Sigma, 
S961825) or vehicle (0.5% ethanol/PBS) was injected intraperitoneally. After 2 h of 
recovery with the dam, pups were placed in a humidified chamber at 35.5°C with 8% 
oxygen. Two h of hypoxia was necessary to obtain a reproducible lesion volume. This HI 
protocol resulted in substantial damage affecting most of the ipsilateral hemisphere. After 
hypoxia, pups were returned to the dam until sacrifice. Sham animals underwent the 
surgical procedure but without ligation of the common carotid artery. For quantification 
of the intact tissue on the side ipsilateral to the lesion, rat pups were perfused with 4% 
paraformaldehyde in PBS (pH 7.4) one week after cerebral HI. Cryostat coronal serial 
sections (50 μm) were cut and stained with cresyl violet (Nissl staining). The areas of 
both intact brain hemispheres and of both hippocampi were measured in sections spaced 
at 500 μm using ImageJ software. The percentage of intact tissue was expressed as 
ipsilateral intact volume/contralateral volume × 100%. 
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Statistical Analyses. Statistical analysis of high-throughput compound screening was 
performed as described above. To compare the means of an experimental group with the 
control group in tissue culture studies, a student’s t-test was used. For analysis of the data 
generated in the neonatal rat cerebral hyoxia-ischemia experiments, JB STAT software 
was used. Each group of data was first examined for distribution normality using 
Shapiro-Wilk tests. In cases of normal distribution, a Welch’s ANOVA test (one-way 
ANOVA with unequal variances) was used followed by a post-hoc Tukey-Kramer test to 
compare the different treatments. When the distribution was not normal, a Kruskal-Wallis 
test (non-parametric analogue of the one-way ANOVA) was used followed by a post-hoc 
Steel-Dwass test to compare the different treatments.  
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SUPPLEMENTAL FIGURE LEGENDS 
 
Fig. S1. Autophagy-inducing peptides trigger cell death. (A) Western blot of LC3 and 
p62 in HeLa cells treated with 20 µM Tat-Scrambled (T-S) or Tat-Beclin 1 (T-B) for 
indicated time points. (B) Cell death of HeLa cells treated with 20 µM T-S or T-B for 
indicated time points. (C) Flow cytometry analysis of propidium-iodide (PI) and Annexin 
V staining in HeLa cells treated with T-B (20 µM). Values represent percentage (mean + 
SEM) of PI+ and Annexin V+/ PI- cells for triplicate samples at each time point. (D) Flow 
cytometry analysis of propidium-iodide (PI) and Annexin V in HeLa cells 5 h after 
treatment with 20 µM T-S, 20 µM T-B, 1 µM staurosporine, or 32 mM H2O2. 
Staurosporine was used as a control treatment for apoptosis induction and H2O2 was used 
as a control treatment for necrosis induction. Values represent percentage (mean + SEM) 
of Annexin V+/PI- and PI+ cells for triplicate samples at each time point. (E) Cell viability 
(measured by CellTiter-Glo assay) of HeLa cells treated with 20 µM T-S or T-B for 
indicated duration. The amount of ATP in untreated control cells (Opti-MEM) was 
standardized as 100%. (F) Sytox Green assay of indicated cell type treated with indicated 
peptide (20 µM, 6 h). (G) Cell viability (measured by CellTiter-Glo assay) of HeLa cells 
treated with T-B (20 µM, 5 h) in the presence of 10 mM 3-methyladenine (3-MA), 100 
µM z-VAD, or 100 µM necrostatin-1 (Nec-1). The amount of ATP in untreated control 
cells (Opti-MEM) was standardized as 100%. (H) Western blot of Beclin 1 and p62 in 
HeLa cells transfected with indicated siRNA and then treated with T-B (20 µM, 3 h). NC, 
non-targeting control siRNA. (I) Western blot of ATG13, ATG14, LC3 and p62 in 
doxycycline (Dox)-inducible U2OS/TR, U2OS/shATG13 and U2OS/shATG14 cells with 
or without Dox (1 µg/ml) for 5 days prior to peptide treatment with T-B (20 µM, 3 h). (J) 
Cell death (measured by Sytox Green assay) of HeLa cells treated with indicated 
concentration of Tat-Beclin 1 + 100 nM bafilomycin A1 (Baf A1) for 6 h. (K) Western 
blot of LC3 and p62 in HeLa cells treated with Tat-Scrambled (20 µM), 20 Tat-Beclin 1 
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(20 µM), or Tat-vFLIP α2 (5 µM) for 5 h. (L) Cell death (measured by Sytox Green assay) 
of HeLa cells treated with indicated concentration of Tat-vFLIP α2 peptide for 5 h. (M) 
Cell death (measured by a Sytox Green assay) of HeLa cells treated with 5 µM Tat-
vFLIP α2 peptide for indicated duration. (N) Cell death (measured by a Sytox Green 
assay) of doxycycline-inducible U2OS/TR and U2OS/shATG14 cells treated with Tat-
Scrambled or Tat-vFLIP α2 peptides (5 µM, 6 h). For B, E-G, J, and L-N, bars represent 
mean + SEM of triplicate samples and similar results were observed in three independent 
experiments. NS, not significant; *P<0.05; **P<0.01; ***P<0.001; t-test. 
 
Fig. S2. Tat-Beclin 1-induced cell death does not involve apoptosis or necroptosis 
and is not inhibited by antioxidants. (A) Clonogenic survival of HeLa cells treated with 
Tat-Beclin 1 (20 µM, 4 h) + 100 µM z-VAD or 100 µM necrostatin-1 (Nec-1). The 
number of colonies in untreated control cells was standardized as 100%. (B) Cell death 
(measured by trypan blue exclusion) of E1A/Ras-transformed wild-type and Bax-/-; Bak-/- 
MEFs treated with 1 µM staurosporine or 20 µM etoposide for 20 h. (C) Representative 
flow cytometry analysis of HeLa cells treated with 20 µM Tat-Scrambled, 20 µM Tat-
Beclin 1, or 1 µM staurosporine for 6 h or 32 mM H2O2 for 4 h and then stained for 
active caspase and propidium iodide (PI). (D) Quantification of the active caspase-
positive population and active caspase-negative/PI-positive population shown in (C). (E) 
TUNEL assay of HeLa cells treated with 20 µM Tat-Scrambled, 20 µM Tat-Beclin 1, 1 
µM staurosporine or 32 mM H2O2 for 8 h. (F) DNA ladder assay of genomic DNA 
purified from HeLa cells treated with 20 µM Tat-Scrambled, 20 µM Tat-Beclin 1 or 1 
µM staurosporine for indicated time period. (G) Assessment of mitochondrial 
cytochrome c release in HeLa cells treated with Tat-Scrambled or Tat-Beclin 1 for 1 h. 
CaCl2 (1 mM) and 0.5% Triton X-100 were used as positive controls. (H) Cell death 
(measured by a Sytox Green assay) of HeLa cells treated with 20 µM Tat-Beclin 1 for 8 h 
+ butylated hydroxyanisole (BHA, 100 µM), propyl gallate (PG, 100 µM), L-glutathione 
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reduced (GSH, 5 mM), or N-acetyl-L-cysteine (NAC, 10 mM). (I) Western blot of 
cleaved caspase 3 and cleaved PARP in HeLa cells treated with 20 µM Tat-Scrambled, 
20 µM Tat-Beclin 1, 5 µM Tat-vFLIP 2, 1 µM staurosporine + 100 µM Z-VAD-FMK 
(z-VAD) for 5 h. For A-B, D, and H, bars represent mean + SEM of triplicate samples 
and similar results were observed in three independent experiments. NS, not significant; 
*P<0.05; ***P<0.001; t-test. 
 
Fig. S3. Morphological features of Tat-Beclin 1-induced autosis. (A) Deconvoluted 
image of lamin A/C staining in HeLa cells treated with Tat-Beclin 1 (20 µM, 5 h). 
Arrows denote concave areas of nuclei with surrounding perinuclear space in autotic cells. 
Scale bar, 20 µm. (B) Representative images of Tom20, lamin A/C and PDI staining in 
HeLa cells treated with Tat-Scrambled (20 µM), Tat-Beclin 1 (20 µM) or Tat-vFLIP α2 
(5 µM) peptides for 5 h and in substrate-adherent HeLa cells following 48 h starvation in 
HBSS. Black arrows indicate representative regions of nuclear concavity and/or enlarged 
perinuclear space. Scale bar, 20 µm. (C) Electron microscopic analysis of HeLa cells 
treated with Tat-Scrambled or Tat-Beclin 1 (20 µM, 5h). N, nucleus, PNS, perinuclear 
space; INM, inner nuclear membrane; ONM, outer nuclear membrane. White arrows 
show dilated and fragmented ER and black arrows show regions where the perinuclear 
space has swollen and contains clumps of cytoplasmic material. Scale bars, 1 µm. 
 
Fig. S4. Starvation induces autosis. (A) Schematic representation of clonogenic survival 
assay of adherent cells subjected to nutrient starvation. HBSS, Hanks Balanced Salt 
Solution. (B) Western blot of ATG7 and Beclin 1 in HeLa cells transfected with indicated 
siRNA for 72 h. Asterisks indicate cross-reacting bands. Quantification of clonogenic cell 
survival of siRNA transfected HeLa cells cultured in normal medium. The colony 
number of NC siRNA-transfected cells was normalized as 100%. (C) Western blot of 
ATG14 in doxycycline (Dox)-inducible U2OS/TR and U2OS/shATG14 cells + Dox 
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treatment (1 µg/ml for 5 days). Quantification of clonogenic cell survival of U2OS/TR 
and U2OS/shATG14 cells cultured in normal medium + 1 µg/ml doxycycline. The colony 
number of cells without doxycycline was normalized as 100%. (D) Western blot of Atg5-
Atg12 conjugate in primary bone marrow derived macrophages (BMDMs) from two 
Atg5fl/fl; Lyz-Cre- and two Atg5fl/fl; Lyz-Cre+ littermate mice. (E) Quantification of 
clonogenic cell survival of BMDMs derived from two Atg5fl/fl; Lyz-Cre- and two Atg5fl/fl; 
Lyz-Cre+ littermate mice cultured in normal medium. The colony number of Atg5fl/fl; 
Lyz-Cre- BMDMs derived from the first mouse was normalized as 100%. For B, C, and 
E, bars represent mean + SEM of triplicate samples and similar results were observed in 
three independent experiments. NS, not significant; t-test. 
 
Fig. S5. Chemical screen to identify inhibitors of autosis. (A) Schematic diagram of 
high-throughput compound screening of inhibitors of Tat-Beclin 1-induced autosis in 
HeLa cells. See SI Materials and Methods for details. (B) Effects of compounds (10 µM) 
with greater than 40% rescue in Table S3 on percentage of cell death in Tat-Beclin 1-
treated HeLa cells (20 µM, 5 h) as measured by Sytox Green-positive staining. 
Representative compounds with less than 40% rescue in Table S3 were also included as 
controls (luteolin, GP4G, nitrendipine, miconazole, sulconazole). (C) 
Immunofluorescence imaging of HeLa cells treated with Tat-Beclin 1 (T-B) or biotin-
Tat-Beclin 1 (b-T-B) (20 µM, 30 min) + either digoxin (10 µM) or suramin (10 µM). 
Biotin-Tat-Beclin 1 was detected using Alexa Fluor 488 streptavidin. Scale bar, 50 µm. 
(D) Quantitation of percentage of cells containing intracellular biotin-Tat-Beclin 1 30 
min following treatment with 20 µM peptide + either digoxin (10 µM) or suramin (10 
µM). (E) Cell death (measured by Sytox Green staining) of HeLa cells after treatment 
with Tat-Beclin 1 (20 µM, 6 h) + 1 µM neriifolin. (F) Measurement of percentage of 
apoptotic cells (Annexin V+/PI-) by FACS analysis in HeLa cells treated with 1 µM 
staurosporine + 5 µM digoxin for 5 h. (G) Cell death (measured by trypan blue exclusion) 
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of HeLa cells treated with 32 mM H2O2 + 5 µM digoxin for indicated time period. (H) 
Cell death (measured by Sytox Green staining) of HeLa cells after treatment with Tat-
Beclin 1 (20 µM, 6 h) or Tat-vFLIP α2 (5 µM, 6 h) in the presence of increasing 
concentrations of digoxin. Values are mean + SEM of triplicate samples. Similar results 
were observed in three independent experiments. (I) Cell death (measured by Sytox 
Green staining) of U2OS cells after treatment with Tat-Beclin 1 (20 µM, 6 h) + 5 µM 
digoxin. (J) Representative electron microscopic image of HeLa cells treated with 5 µM 
digoxin for 5 h. Scale bar, 1 µm. (K) Western blot ]of LC3 and p62 in HeLa cells 
following treatment with Tat-Beclin 1 (20 µM, 4h) (left gels) or after 4 h starvation (right 
gels) in the presence of indicated dose of digoxin. (L) Expression analysis of p62 and 
LC3B (measured by RT-PCR) in HeLa cells treated with Tat-Scrambled or Tat-Beclin 1 
(20 µM, 4 h) or starved for 4 h + 1 µM digoxin. (M) Western blot of cleaved caspase 3 
and cleaved PARP in HeLa cells treated with Tat-Scrambled (20 µM), Tat-Beclin 1 (20 
µM), or staurosporine (1 µM) + 100 µM z-VAD or 5 µM digoxin for 5 h. For B, D-G, 
and I, bars represent mean + SEM of triplicate samples and similar results were observed 
in three independent experiments. NS, not significant; *P<0.05;***P<0.001; t-test. 
 
Fig. S6. Na+, K+-ATPase regulates autosis. (A) Western blot of LC3, p62 and the α1 
subunit of Na+, K+-ATPase in siRNA transfected HeLa cells (72 h) treated with Tat-
Beclin 1 (20 µM, 4 h) or starvation (4 h). (B) Western blot of Na+, K+-ATPase α1-subunit 
in HeLa cells transfected with a pool of three Na+,K+-ATPase α1 siRNAs (NaK-1 
siRNA 1, NaK-1 siRNA 2, NaK-1 siRNA 3 shown in (A)) for 72 h. (C) Expression 
analysis of p62 and LC3 (measured by RT-PCR) in HeLa cells transfected with the 
indicated siRNA for 72 h and then treated with Tat-Scrambled or Tat-Beclin 1 (20 µM, 4 
h) or starved for 4 h. (D) Quantitation of percentage of HeLa cells with intracellular 
biotin-Tat-Beclin 1 staining treated with 20 µM peptide for 30 min after NC-siRNA or 
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NaK-α1 siRNA transfection for 72 h. Biotin-Tat-Beclin 1 was detected using Alexa Fluor 
488 streptavidin. (E) Western blot of Na+, K+-ATPase α1-subunit in U2OS cells 
transfected with Na+, K+-ATPase α1 siRNA 1 for 72 h. (F) Cell death (measured by 
Sytox Green staining) of U2OS transfected with indicated siRNA for 72 h and then 
treated with Tat-Scrambled or Tat-Beclin 1 (20 µM, 6 h). (G) Western blot of Na+,K+-
ATPase α1-subunit in NIH3T3 cells transfected with NaK-1 siRNA (mouse) for 72 h. 
(H) Cell death (measured by Sytox Green staining) of NIH3T3 cells transfected with 
indicated siRNA for 72 h and then treated with Tat-Scrambled or Tat-Beclin 1 (20 µM, 6 
h). (I) Cell death (measured by Sytox Green staining) of HeLa cells transfected with 
indicated siRNA for 72 h, and then treated with Tat-Scrambled (20 µM), Tat-Beclin 1 (20 
µM), or Tat-vFLIP α2 (5 µM) + 10 µM digoxin for 6 h. For D, F, and H-I, bars represent 
mean + SEM of triplicate samples and similar results were observed in three independent 
experiments NS, not significant; ***P<0.001; t-test. 
 
Fig. S7. Neonatal hypoxic-ischemic brain damage and hippocampal CA3 region 
autophagy and autosis are reduced by treatment with the cardiac glycoside, 
neriifolin. (A) Nissl-stained sections showing the effects of neriifolin treatment on the 
hippocampus one week after hypoxia-ischemia (HI). Neriifolin treatment protected 
almost all the   hippocampus (lower panels) including the CA3 region (lower right panel) 
compared to vehicle-treated pups exposed to HI (middle panels). Scale bars, 100 µm. (B) 
Nissl-stained sections showing the effects of neriifolin treatment on the CA3 region of 
the hippocampus 24 h after HI exposure in rat pups treated with vehicle or neriifolin. 
Scale bars, 100 µm. (C) Immunohistochemistry to detect LC3 and LAMP1 in the CA3 
region of the hippocampus 24 h after neonatal HI with indicated treatment. Scale bars, 
100 µm (low magnifications); 20 µm (high magnifications).  
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